COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of Gabapentin in Diabetic Peripheral Neuropathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00712439
Recruitment Status : Completed
First Posted : July 10, 2008
Last Update Posted : June 8, 2011
Information provided by:

Brief Summary:
The purpose of this study is to determine whether a new Gabapentin tablet, is safe and effective for the treatment of painful diabetic peripheral neuropathy.

Condition or disease Intervention/treatment Phase
Diabetic Peripheral Neuropathy Drug: Gabapentin Extended Release tablets Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 147 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy
Study Start Date : April 2006
Actual Primary Completion Date : November 2006
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1 Drug: Gabapentin Extended Release tablets
Placebo Comparator: 2 Drug: Placebo

Primary Outcome Measures :
  1. The primary study objective is to assess the relative efficacy of G-ER versus placebo in reducing the mean daily pain score from the baseline week to end of efficacy treatment period (Treatment Week 4) in patients with DPN. [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Secondary efficacy measures will include changes from baseline in average daily sleep interference scores, SF-MPQ, BPI,NPS, PGIC, and CGIC. [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women 18 years or older with diagnosis of type 1 or type 2 diabetes who have reported symmetrical painful symptoms in distal extremities for 1-5 years prior to the study and whose symptoms are attributable to sensorimotor diabetic peripheral neuropathy (DPN).
  • Patients of childbearing potential must have a negative urine pregnancy test at screening/randomization, and must use medically acceptable methods of birth control.
  • Patient has pain score of at least 4 on the 11-point Likert numerical rating scale at screening. Potential patients should not be informed of the pain intensity eligibility criterion prior to screening or randomization.
  • Patient has a mean baseline week pain intensity of at least 4 on the 11-point Likert scale at the end of a one-week pre-treatment period and has completed at least 4 days of diary entries during the baseline week.
  • Patient is on stable regimen of antidiabetes medication at screening that can be maintained during the study.
  • Patient has hemoglobin A1c (HbA1c) ≤11% at screening.
  • Patient has FPG ≤310 mg/dL at screening.
  • Patient must have a minimum washout of greater than 5 times the half-life of the drug of any of several medications
  • Patients currently treated with gabapentin or pregabalin at screening may be eligible for the study, but must have tapering period wherein the dose of gabapentin is reduced gradually over a period of at least 7 days plus a 2-day or 3-day washout of gabapentin or pregabalin, respectively, prior to start of the Baseline Week.
  • Patient must have adequate eyesight to complete questions on the DiaryPro and SitePro. If a patient is unable to do so (for reasons other than severe eye disease) but a caregiver is available to complete these tasks following instruction from the patient, the caregiver may be trained to accomplish these tasks

Exclusion Criteria:

  • Patients who have previously not responded to treatment for DPN with gabapentin at doses of ≥1200 mg/day or pregabalin at doses ≥300 mg/day.
  • Patients who previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.
  • Patient has hypersensitivity to gabapentin.
  • Patient is a nursing mother.
  • Patient has used injected anesthetics or steroids within 30 days of baseline.
  • Patient has certain conditions that could confound evaluation of painful DPN, in particular, amputations other than toes, non-diabetic neurologic disorders (e.g. phantom limb pain), and skin conditions affecting sensation in painful limbs.
  • Patient has skin conditions in the area affected by the neuropathy that could alter sensation.
  • Patient is in an immunocompromised state.
  • Patient has an estimated creatinine clearance of <60 ml/min calculated using the Cockroft Gault method (Appendix 3).
  • Patient has had malignancy within past 2 years other than basal cell carcinoma.
  • Patient has had gastric reduction surgery.
  • Patient has severe chronic diarrhea, chronic constipation [unless attributed to drugs that will be washed out], uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
  • Patient has any abnormal chemistry or hematology results that are deemed by the investigator to be clinically significant.
  • Patient has a history of substance abuse within the past year.
  • Patient has had 1 or more visits to an emergency room or hospital within the previous 30 days due to hypoglycemia.
  • Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.
  • Patient has a history of pernicious anemia, untreated hypothyroidism, chronic hepatitis B or C, hepatitis within the past 3 months, or HIV infection.
  • Patient has any other serious medical condition that, in the opinion of the Investigator would jeopardize the safety of the patient or affect the validity of the study results.
  • Continuing use of any concomitant medication excluded by Inclusion Criterion 8.
  • Patient has participated in a clinical trial of an investigational drug or device within 30 days of the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00712439

Sponsors and Collaborators
Layout table for investigator information
Study Director: Rekha Sathyanarayana Depomed
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Lynne Rowe, Depomed Identifier: NCT00712439    
Other Study ID Numbers: 81-0046
First Posted: July 10, 2008    Key Record Dates
Last Update Posted: June 8, 2011
Last Verified: June 2011
Keywords provided by Depomed:
Additional relevant MeSH terms:
Layout table for MeSH terms
Peripheral Nervous System Diseases
Diabetic Neuropathies
Neuromuscular Diseases
Nervous System Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antimanic Agents